Table 2 Clinical characteristics and laboratory biomarkers among the extended population
From: Risk prediction models of gestational diabetes mellitus before 16 gestational weeks
Variable | Training cohort (n = 1481) | Validation cohort (n = 635) | p |
|---|---|---|---|
Age (year) | 30.0 (27.0–32.0) | 29.0 (27.0–32.0) | 0.438 |
Nulliparous, n (%) | Â | Â | 0.147 |
 No | 898 (60.6) | 407 (64.1) |  |
 Yes | 583 (39.4) | 228 (35.9) |  |
History of GDM, n (%) | Â | Â | 0.109 |
 No | 1406 (94.9) | 591 (93.1) |  |
 Yes | 75 (5.1) | 44 (6.9) |  |
History of macrosomia, n (%) | Â | Â | 0.999 |
 No | 1456 (98.3) | 625 (98.4) |  |
 Yes | 25 (1.7) | 10 (1.6) |  |
History of abnormal pregnancy, n (%) | Â | Â | 0.845 |
 No | 1427 (96.4) | 610 (96.1) |  |
 Yes | 54 (3.6) | 25 (3.9) |  |
Family history of DM, n (%) | Â | Â | 0.911 |
 No | 1458 (98.4) | 624 (98.3) |  |
 Yes | 23 (1.6) | 11 (1.7) |  |
PCOS, n (%) | Â | Â | 1.000 |
 No | 1457 (98.4) | 624 (98.3) |  |
 Yes | 24 (1.6) | 11 (1.7) |  |
Pre-pregnancy BMI (kg/m2) | 20.5 (18.9–22.7) | 20.6 (18.9–22.6) | 0.631 |
WBC (109/L) | 9.0 (7.8–10.4) | 9.2 (7.8–10.5) | 0.248 |
NEUT (%) | 72.8 (68.7–76.5) | 72.9 (68.9–76.6) | 0.384 |
RBC (1012/L) | 4.0 (3.8–4.3) | 4.0 (3.8–4.3) | 0.816 |
HGB (g/L) | 121.1 (114.3–128.0) | 121.0 (114.0–128.0) | 0.950 |
HCT (%) | 36.1 (34.0–38.0) | 36.0 (33.8–37.9) | 0.667 |
PLT (109/L) | 235.0 (203.0–270.5) | 233.0 (202.5–271.0) | 0.826 |
MPV (fL) | 9.1 (8.3–10.1) | 9.2 (8.3–10.0) | 0.494 |
ALT (U/L) | 12.0 (9.0–19.0) | 12.0 (9.0–17.0) | 0.186 |
AST (U/L) | 16.0 (13.9–20.0) | 16.0 (13.5–19.0) | 0.190 |
Creatinine (μmol/L) | 46.6 (41.4–53.0) | 46.0 (41.5– 52.5) | 0.416 |
Uric acid (μmol/L) | 237.0 (204.0–275.0) | 235.0 (201.0–275.3) | 0.793 |
FBG (mmol/L) | 4.5 (4.2–4.9) | 4.5 (4.2–4.9) | 0.344 |
PT (s) | 12.3 (10.9–12.8) | 12.3 (10.1–12.8) | 0.812 |
APTT (s) | 32.6 (29.0–34.9) | 32.3 (28.8–34.6) | 0.213 |
FIB (mg/dL) | 4.1 (3.7–4.5) | 4.1 (3.7–4.5) | 0.775 |
PAPP-A (MoM) | 1.1 (0.7–1.6) | 1.1 (0.7–1.6) | 0.330 |